CRIS, a drug development company focused on developing the next generation of proprietary targeted medicines for cancer treatment, today announced that the Company will be presenting at the 2008 Boston Biotech R&D Conference, at 9:00 a.m. EDT on October 22, 2008, at Harvard Medical School in Cambridge, Mass.
Daniel R. Passeri, Curis' President and Chief Executive Officer, will provide an overview of the status of GDC-0449, an orally-administered small molecule inhibitor of the Hedgehog pathway that is currently in Phase II clinical testing under collaboration with Genentech. Mr. Passeri also will discuss CUDC-101, CUDC-305 and Curis' other targeted cancer programs, in addition to other corporate activities.
About Curis, Inc.
Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. In expanding its drug development efforts in the field of cancer through its targeted cancer drug development platform, Curis is building upon its previous experiences in targeting signaling pathways for the development of next generation targeted cancer therapies. For more information, visit Curis' website at www.curis.com.
About the Boston Biotech R&D Conference
The 2008 Boston Biotech R&D Conference willtake place at Harvard Medical School and will highlight the work of top academics as well as up-and-coming biotech companies in the Boston area. The agenda features keynotes from several luminaries in medicine and research, including Jeffrey S. Flier, Dean of Harvard Medical School,Leonard Guarente, Ronald Kahn, Eric S. Lander, Robert Langer, Phillip Sharp, David Sinclair, as well asCEOs of the next generation of leading biotech and pharma companies from the Boston area. The conference is sponsored by Alexandria Real Estate Equities Inc., Pure Communications Inc., and Rodman & Renshaw, LLC. For more information, visit www.bostonbiotechconference.com.
SOURCE: Curis, Inc.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment